Definition:
ADI-PEG-20 is a drug that depletes arginine, an amino acid essential for the growth of certain cancer cells, including mesothelioma cells. It is a pegylated form of arginine deiminase, an enzyme that breaks down arginine, and is used in experimental treatments for cancers linked to asbestos exposure.
Phonetic Pronunciation:
(AH-dee-PEH-guh-twen-tee)
Etymological Origin:
The term "ADI" stands for arginine deiminase, the enzyme that depletes arginine. "PEG" refers to polyethylene glycol, a chemical modification that enhances the drug's stability and reduces immune reactions. The "20" likely refers to a specific formulation or molecular weight of the compound.
Significance in Asbestos Context:
ADI-PEG-20 is significant in the context of asbestos-related diseases because it represents a potential therapeutic option for mesothelioma, a cancer strongly associated with asbestos exposure. Mesothelioma cells often rely on external sources of arginine for survival, and ADI-PEG-20 exploits this dependency to inhibit tumor growth. This drug is particularly relevant in research and clinical trials aimed at improving outcomes for mesothelioma patients.
Synonyms or Related Terms:
Example Sentence:
"Clinical trials are investigating the efficacy of ADI-PEG-20 in treating mesothelioma, a cancer caused by prolonged asbestos exposure, by targeting the tumor's dependence on arginine."
Common Misconceptions:
